Advertisement

Topics

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

2019-04-17 12:53:13 | BioPortfolio

Published on BioPortfolio: 2019-04-17T12:53:13-0400

Clinical Trials [1428 Associated Clinical Trials listed on BioPortfolio]

Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia

Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this study is to learn if inotuzumab ozogamicin given in combination ...

Study of Inotuzumab Ozogamicin in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

The goal of this clinical research study is to learn how well low-dose inotuzumab ozogamicin may help to control acute lymphocytic leukemia (ALL). The safety of the study drug will also be...

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

This study will explore 2 different doses of inotuzumab ozogamicin including the dose that is approved and a lower dose. The main purpose of this study is to evaluate whether a dose of ino...

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

The trial proposed to evaluate the efficacy and safety of an inotuzumab ozogamicin followed by an age-adapted intermediate intensive consolidation therapy and maintenance treatment in pati...

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given ...

PubMed Articles [434 Associated PubMed Articles listed on BioPortfolio]

Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.

Inotuzumab ozogamicin is a novel antibody-drug conjugate that targets CD22, a common antigen on pre-B acute lymphoblastic leukemia cells.

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.

In the absence of head-to-head trials, this analysis aimed to provide a fair indirect comparison of the efficacy between blinatumomab and inotuzumab ozogamicin (InO), two treatments for adult patients...

Risk Factors for Development of and Progression of Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome.

Veno-occlusive disease, also known as sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening complication of allogeneic or autologous hematopoietic stem cell transplantation (HSC...

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

The outcome of older patients with newly diagnosed, Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) is poor. The combination of targeted therapy with low-intensity chemotherap...

Emergent radiation for leukemic optic nerve infiltration in a child receiving intrathecal methotrexate.

Vision loss caused by leukemic infiltration of the optic nerve is an oncologic emergency. To maintain vision, radiotherapy must be initiated quickly. However, many pediatric acute lymphoblastic leukem...

Medical and Biotech [MESH] Definitions

A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies.

Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

A PREDNISOLONE derivative with similar anti-inflammatory action.

A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.

More From BioPortfolio on "Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial